Neuronal Nitric Oxide Synthase (nNOS, NOS1) rs693534 and rs7977109 Variants and Risk for Migraine.
OBJECTIVE
Many biochemical, pharmacological, neuropathological, and experimental data suggest a possible role of nitric oxide in the pathogenesis of migraine. We investigated the possible association between functional single nucleotide polymorphisms (SNPs) in the neuronal nitric oxide synthase gene (NOS1 or nNOS; chromosome 12q24.22) and the risk for migraine.


METHODS
We studied the frequency of the of rs7977109 and rs693534 genotypes and allelic variants in 197 patients with migraine and 308 healthy controls using a TaqMan-based qPCR assay. As a secondary analysis, we studied the possible influence of gender, age at onset of migraine, positive family history of migraine, and presence or absence of aura on the genotypes frequency.


RESULTS
The frequencies of rs7977109 and rs693534 genotypes and allelic variants were not associated with the risk for migraine with OR for minor alleles = 0.94 (95% CI 0.72-1.23) and = 0.88 (0.68-1.15), respectively, and the lack of association was not influenced by gender, age at onset of migraine, positive family history of migraine, and presence or absence of aura.


CONCLUSIONS
NOS1 rs7977109 and rs693534 genotypes and allelic variants are not associated with the risk for migraine in Caucasian Spanish people.
Department of Pharmacology, University of Extremadura, Cáceres, Spain.|Red de Investigación de Reacciones Adversas a Alergenos y Fármacos, Instituto de Salud Carlos III, Madrid, Spain.|AMGenomics, Cáceres, Spain.
Elena
E
García-Martín
Red de Investigación de Reacciones Adversas a Alergenos y Fármacos, Instituto de Salud Carlos III, Madrid, Spain.|Department of Pharmacology, University of Extremadura, Badajoz, Spain.
Carmen
C
Martínez
Department of Family Medicine, Hospital "Príncipe de Asturias,", Universidad de Alcalá, Madrid, Spain.
Mercedes
M
Serrador
Section of Neurology, Hospital Universitario del Sureste, Madrid, Spain.|Department of Medicine-Neurology, Hospital "Príncipe de Asturias,", Universidad de Alcalá, Madrid, Spain.
Hortensia
H
Alonso-Navarro
Section of Neurology, Hospital Universitario del Sureste, Madrid, Spain.|Service of Neurology, Hospital "Ramón y Cajal,", Universidad de Alcalá, Madrid, Spain.
Francisco
F
Navacerrada
Department of Medicine-Neurology, Hospital "Príncipe de Asturias,", Universidad de Alcalá, Madrid, Spain.
Esteban
E
García-Albea
Department of Pharmacology, University of Extremadura, Cáceres, Spain.|Red de Investigación de Reacciones Adversas a Alergenos y Fármacos, Instituto de Salud Carlos III, Madrid, Spain.|AMGenomics, Cáceres, Spain.
José A G
JA
Agúndez
Section of Neurology, Hospital Universitario del Sureste, Madrid, Spain.|Department of Medicine-Neurology, Hospital "Príncipe de Asturias,", Universidad de Alcalá, Madrid, Spain.
Félix Javier
FJ
Jiménez-Jiménez
D000328:Adult; D005260:Female; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005838:Genotype; D006801:Humans; D008297:Male; D008881:Migraine Disorders / Q000235:genetics*; D052248:Nitric Oxide Synthase Type I / Q000235:genetics*; D016133:Polymerase Chain Reaction; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors; D013030:Spain; D044465:White People / Q000235:genetics
C496320:NOS1 protein, human; D052248:Nitric Oxide Synthase Type I
genetic polymorphism; genetics; migraine; nitric oxide; nitric oxide synthase genes; risk factor